chevron_leftBack
As of 24 April 2025, Exact Sciences Corp. has a market cap of $8.19B USD, ranking #1981 globally and #690 in the United States. It ranks #172 in the Healthcare sector, and #21 in the Diagnostics & Research industry.
Key Stats
Market Cap
$8.19BUSD
Enterprise Value
$9.93BUSD
Revenue (TTM)
$2.76BUSD
EBITDA (TTM)
$29.76MUSD
Net Income (TTM)
-$1.03BUSD
EBITDA Margin
1.1%
Profit Margin
-37%
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Kevin Conroy
open_in_new
Employees
7,000
Founded
1995
Website
exactsciences.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -0.1% | 4.3% | -3.4% | -20% | -38% | -29% |
Upcoming Earnings
Earnings Date
Thu, May 1
Earnings Time
bedtime
After Close
EPS Estimate
-$0.2700
Revenue Estimate
$698.6M
9.6% yoy
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
EXAS
Exact Sciences Corp
ISIN: US30063P1057
Shares Out.:
Shares Outstanding:
185.755M1
Shares Float:
182.931M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
44.09 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Exact Sciences Corp.
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
